DE602004022187D1 - 4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs - Google Patents

4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs

Info

Publication number
DE602004022187D1
DE602004022187D1 DE602004022187T DE602004022187T DE602004022187D1 DE 602004022187 D1 DE602004022187 D1 DE 602004022187D1 DE 602004022187 T DE602004022187 T DE 602004022187T DE 602004022187 T DE602004022187 T DE 602004022187T DE 602004022187 D1 DE602004022187 D1 DE 602004022187D1
Authority
DE
Germany
Prior art keywords
ylamino
pyrazol
cancer
treatment
pyrimidine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004022187T
Other languages
English (en)
Inventor
Thorsten Nowak
Andrew Peter Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34525049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004022187(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0324335A external-priority patent/GB0324335D0/en
Priority claimed from GB0412194A external-priority patent/GB0412194D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE602004022187D1 publication Critical patent/DE602004022187D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004022187T 2003-10-17 2004-10-11 4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs Active DE602004022187D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0324335A GB0324335D0 (en) 2003-10-17 2003-10-17 Novel compounds
GB0412194A GB0412194D0 (en) 2004-06-02 2004-06-02 Novel compounds
PCT/GB2004/004307 WO2005040159A1 (en) 2003-10-17 2004-10-11 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
DE602004022187D1 true DE602004022187D1 (de) 2009-09-03

Family

ID=34525049

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004022187T Active DE602004022187D1 (de) 2003-10-17 2004-10-11 4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs

Country Status (16)

Country Link
US (1) US7579349B2 (de)
EP (1) EP1678169B1 (de)
JP (1) JP2007510626A (de)
KR (1) KR20060123164A (de)
AR (1) AR046338A1 (de)
AU (1) AU2004283137A1 (de)
BR (1) BRPI0415398A (de)
CA (1) CA2542522A1 (de)
DE (1) DE602004022187D1 (de)
ES (1) ES2328820T3 (de)
IL (1) IL174989A0 (de)
NO (1) NO20062130L (de)
SA (1) SA04250338B1 (de)
TW (1) TW200530229A (de)
UY (1) UY28565A1 (de)
WO (1) WO2005040159A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03002299A (es) 2000-09-15 2003-06-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2004072029A2 (en) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
US20070185100A1 (en) * 2004-02-18 2007-08-09 Astrazeneca Ab Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
JP2008516973A (ja) 2004-10-15 2008-05-22 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
BRPI0517737A (pt) 2004-11-17 2008-10-21 Miikana Therapeutics Inc inibidores de quinase
AU2005322855B2 (en) 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
EP1863797A1 (de) * 2005-03-23 2007-12-12 AstraZeneca AB 2-azetidinyl-4-(lh-pyrazol-3-ylamino)pyrimidine als inhibitoren der aktivität des rezeptors für den insulin-like growth factor-i
GB0506886D0 (en) * 2005-04-05 2005-05-11 Astrazeneca Ab Chemical compounds
US20080167297A1 (en) * 2005-04-05 2008-07-10 Astrazeneca Ab Pyrimidine Derivatives for Use as Anticancer Agents
WO2007023382A2 (en) * 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
JP2009508833A (ja) * 2005-09-16 2009-03-05 アストラゼネカ アクチボラグ Ｉｇｆ−１ｒチロシンキナーゼ活性の阻害のためのピリミジン誘導体類
ES2535854T3 (es) * 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7820685B2 (en) 2005-11-03 2010-10-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
AU2006315334B2 (en) * 2005-11-16 2011-05-19 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP5161072B2 (ja) * 2006-04-27 2013-03-13 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
CA2654852A1 (en) * 2006-06-30 2008-01-03 Astrazeneca Ab Pyrimidine derivatives useful in the treatment of cancer
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
DE602007004750D1 (de) 2006-11-02 2010-03-25 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
NZ577768A (en) * 2006-12-19 2012-01-12 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
ES2374335T3 (es) * 2007-03-09 2012-02-15 Vertex Pharmaceuticals Incorporated Aminopirimidinas útiles como inhibidores de proteína quinasas.
ES2435997T3 (es) 2007-03-09 2013-12-26 Vertex Pharmaceuticals, Inc. Aminopirimidinas útiles como inhibidores de las proteínas cinasas
US20080269266A1 (en) * 2007-03-27 2008-10-30 Astrazeneca Ab Novel compounds 747
EP2146982A2 (de) 2007-04-13 2010-01-27 Vertex Pharmaceuticals Incorporated als kinaseinhibitoren geeignete aminopyrimidine
NZ580884A (en) 2007-05-02 2012-02-24 Vertex Pharma Thiazoles and pyrazoles useful as kinase inhibitors
JP5389786B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
EP2166849A4 (de) * 2007-06-11 2010-09-15 Miikana Therapeutics Inc Substituierte pyrazol-verbindungen
EP2176261B1 (de) * 2007-07-31 2012-12-19 Vertex Pharmaceuticals Incorporated Verfahren für die zubereitung von 5-fluor-1h-pyrazolo [3, 4-b] pyridin-3-amin und derivaten davon
WO2009019518A1 (en) * 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
JP2012521425A (ja) * 2009-03-23 2012-09-13 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
EP2411011A4 (de) * 2009-03-24 2012-08-15 Msd Kk Neue aminopyridinderivate mit selektiver aurora-a-hemmung
US20110053916A1 (en) 2009-08-14 2011-03-03 Vertex Pharmaceuticals Incorporated Pyrimidine compounds as tuberculosis inhibitors
ES2553620T3 (es) 2009-12-21 2015-12-10 Bayer Cropscience Ag Bis(difluorometil)pirazoles como fungicidas
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
EP2423210A1 (de) 2010-08-25 2012-02-29 Bayer CropScience AG Heteroarylpiperidin- und -piperazinderivate als Fungizide
JP5918773B2 (ja) 2010-10-27 2016-05-18 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 殺菌剤としてのヘテロアリールピペリジンおよびヘテロアリールピペラジン誘導体
BR112013019667B1 (pt) 2011-02-01 2019-07-02 Bayer Intellectual Property Gmbh Compostos derivados de heteroaril-piperidina e -piperazina, seus usos, composição, processos de produção de compostos e de composições, método para o controle de fungos fitopatogênicos prejudiciais
EP2532233A1 (de) 2011-06-07 2012-12-12 Bayer CropScience AG Wirkstoffkombinationen
IN2014CN01862A (de) 2011-09-15 2015-05-29 Bayer Ip Gmbh
DK2921493T3 (da) 2011-12-27 2017-11-27 Bayer Ip Gmbh Heteroarylpiperidin og ¿piperazinderivater
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2018193387A1 (en) 2017-04-19 2018-10-25 Pi Industries Ltd. Heterocyclic compounds with microbiocidal properties
WO2020014599A1 (en) * 2018-07-13 2020-01-16 Teqla Therapeutics, Inc. Use of bcl6 inhibitors for treating autoimmune diseases
AR120377A1 (es) 2019-11-11 2022-02-09 Pi Industries Ltd Derivados heteroaromáticos de sulfiliminas o sulfoximinas con actividad fungicida
AR120376A1 (es) 2019-11-11 2022-02-09 Pi Industries Ltd Heteroaril piperidiniletanonas sustituidas con actividad fungicida
UY38940A (es) 2019-11-11 2021-06-30 Pi Industries Ltd Nuevas piridiniloxi piperidiniletanonas sustituidas
TW202237143A (zh) 2020-12-10 2022-10-01 南韓商Ｌｇ化學股份有限公司 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物
WO2022211595A1 (ko) * 2021-04-01 2022-10-06 주식회사 엘지화학 옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물
EP4349331A1 (de) * 2021-06-04 2024-04-10 Kyoto Pharmaceutical University Amp-aktivierter proteinkinaseaktivator
TW202348225A (zh) * 2022-02-25 2023-12-16 美商納羅醫療公司 Myc家族原癌基因蛋白之調節劑
WO2023163712A1 (en) * 2022-02-25 2023-08-31 Nalo Therapeutics Modulators of myc family proto-oncogene protein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2426180A1 (de) 1974-05-29 1975-12-18 Bayer Ag Verfahren zum faerben von polyurethankunststoffen
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
US6337338B1 (en) 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
CZ300712B6 (cs) 1999-09-24 2009-07-22 Janssen Pharmaceutica N. V. Cásticová farmaceutická kompozice, pevná disperze a farmaceutická dávková forma, zpusoby jejich prípravy a použití a obchodní balení s jejich obsahem
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ES2559273T3 (es) 2000-05-08 2016-02-11 Janssen Pharmaceutica Nv Profármacos de pirimidinas que inhiben la replicación del VIH
MXPA03002299A (es) 2000-09-15 2003-06-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
MXPA03005605A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds

Also Published As

Publication number Publication date
IL174989A0 (en) 2006-08-20
SA04250338B1 (ar) 2008-11-18
AU2004283137A1 (en) 2005-05-06
CA2542522A1 (en) 2005-05-06
WO2005040159A1 (en) 2005-05-06
US7579349B2 (en) 2009-08-25
US20070037888A1 (en) 2007-02-15
ES2328820T3 (es) 2009-11-18
UY28565A1 (es) 2005-05-31
EP1678169B1 (de) 2009-07-22
TW200530229A (en) 2005-09-16
JP2007510626A (ja) 2007-04-26
BRPI0415398A (pt) 2006-12-19
AR046338A1 (es) 2005-12-07
EP1678169A1 (de) 2006-07-12
KR20060123164A (ko) 2006-12-01
NO20062130L (no) 2006-05-12

Similar Documents

Publication Publication Date Title
DE602004022187D1 (de) 4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs
ATE433978T1 (de) 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
ATE477249T1 (de) Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes
DE602006010401D1 (de) Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE60324166D1 (de) Dihydropyridinderivaten zur verwendung als inhibitoren der menschlichen neutrophilenelastase
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
ATE374610T1 (de) 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
DE602004021037D1 (de) Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
NO20055588D0 (no) Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2
ATE315554T1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DE602005017468D1 (de) Pyrimidinderivate zur verwendung als vanilloidrezeptorliganden und deren verwendung bei der behandlung von schmerzen
DE602005009318D1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
ATE468331T1 (de) Neue cyanopyridine-derivate zur behandlung von krebs und anderer erkrankungen
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
DE602005009255D1 (de) Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
ATE417842T1 (de) Verwendung von trisubstituierten benzopyranonen
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE60322052D1 (de) N-acylaminoacetonitril-derivate und ihre verwendung zur kontrolle von parasiten
DE602006018331D1 (de) 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition